Director, Global Oncology Pricing Reimbursement & Access, Non-alliance & Early Asset Lead
il y a 7 jours
In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas cen...